Received Mar 18, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | UNK | Unknown | PO / MO |
The patient took the full course of treatment with Vivotif, after the patient took the last dose, the patient relized that the vaccine expired in Feb-2025; Case reference number US-BN-2025-000421 is a spontaneous case initially received from nurse via Communication (reference number: USBAV25-0737) on 02-Apr-2025 and concerns a female patient of unspecified age. The patient's medical history and concomitant medication details were not provided. On unspecified dates, the patient took the full course of Vivotif vaccine (batch number: unknown; expiration date: Feb-2025) orally, at unknown dose, for indication protection against typhoid fever. As reported, after the patient took the last dose, patient realized that the pharmacy gave the patient Vivotif that expired in Feb-2025 (explicitly coded as 'Expired vaccine used'). At the time of the initial report, it was unknown if the patient experienced any of the adverse events due to Vivotif. No further information was provided.; Reporter's Comments: A female patient of unspecified age took the full course of Vivotif vaccine for indication protection against typhoid fever. As reported, after the patient took the last dose, patient realized that the pharmacy gave the patient Vivotif that expired in Feb-2025, which is considered as expired vaccine used. It was unknown if the patient experienced any of the adverse events due to Vivotif. Expired product administered is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Expired product administered is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: A female patient of unspecified age took the full course of Vivotif vaccine for indication protection against typhoid fever. As reported, after the patient took the last dose, patient realized that the pharmacy gave the patient Vivotif that expired in Feb-2025, which is considered as expired vaccine used. It was unknown if the patient experienced any of the adverse events due to Vivotif. Expired product administered is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Expired product administered is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Comments: NONE